肝疾患診療に役立つ　肝線維化評価テキスト

出版社： 文光堂
著者：
発行日： 2017-09-19
分野： 臨床医学：内科  >  肝/胆/膵
ISBN： 9784830621000
電子書籍版： 2017-09-19 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,950 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,950 円(税込)

購入する

商品紹介

B型・C型肝炎，脂肪肝などの肝疾患において，肝線維化は病気の進行度や発癌リスクの予測をする上でもっとも重要なファクターである．しかし，現在，肝線維化評価のゴールドスタンダードである肝生検は侵襲性とサンプリングエラーなどの問題がある．本書では，肝生検にかわり，非侵襲的に肝全体の線維化の程度を評価できる有用な検査法として期待されるデバイスや線維化マーカー，スコアリングの概要から臨床への応用について，第一線の専門家が余すところなく解説した．

目次

  • 肝疾患診療に役立つ　肝線維化評価テキスト

    ―目次―

    第1章　肝線維化評価の臨床的意義

    第2章　肝線維化の非侵襲的評価方法
    　1　肝線維化スコアリング（Fib-4 index，APRI，FibroIndex など）
    　2　バイオマーカー
    　　１）血清線維化マーカー
    　　２）M2BPGi
    　　３）ELF score
    　3　遺伝子
    　4　超音波elastography
    　　１）Transient elastography（TE）
    　　２）Real-time tissue elastography（RTE）
    　　３）Shear wave elastography
    　5　MR elastography
    　6　MR laparoscopy

    第3章　臨床への展開
    　1　非侵襲的手法の組み合わせによる肝線維化評価
    　2　肝癌のリスクを予測する
    　3　食道胃静脈瘤の存在を予測する
    　4　治療が必要なB型肝炎を見分ける
    　5　C型肝炎ウイルス排除後の病態を見極める
    　6　自己免疫性肝疾患の病態を診断する
    　7　脂肪肝の中からNASHを見分ける
    　8　肝生検で得られる付加的情報とは

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 肝線維化評価の臨床的意義

P.6 掲載の参考文献
1) Bedosssa, P. et al. : Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994 ; 20 (1) : 15-20
 
2) Cadranel, J. F. et al. : Practices of liver biopsy in France : results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000 ; 32 (3) : 477-481
 
3) 泉並木 (監修) : 肝硬変の成因別実態 2014, 医学図書出版, 2015
 
4) 日本肝臓学会肝炎診療ガイドライン作成委員会 (編) : B型肝炎治療ガイドライン (第3版), 2017年8月 (https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b)
 
5) 日本肝臓学会肝炎診療ガイドライン作成委員会 (編) : C型肝炎治療ガイドライン (第5.4版), 2017年4月 (https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c)
 
6) 高後裕 (監修) : 我が国における非B非C肝硬変の実態調査 2011, 響文社, 2012 (https://www.jsh.or.jp/doc/guidelines/kankouhen.pdf)
 

第2章 肝線維化の非侵襲的評価方法

P.12 掲載の参考文献
1) 孝田雅彦 : 血清線維化マーカーとスコア診断. 肝胆膵 2016 ; 73 (6) : 993-1000
 
2) Wai, C. T. et al. : A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 ; 38 (2) : 518-526
 
3) Forns, X. et al. : Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002 ; 36 (Issue 4) : 986-992
 
4) Koda, M. et al. : FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007 ; 45 (2) : 297-306
 
5) Vallet-Pichard, A. et al. : FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007 ; 46 (1) : 32-36
 
6) Imbert-Bismut, F. et al. : Biochemical markers of liver fibrosis in patients with hepatitis C virus infection : a prospective study. Lancet 2001 ; 357 (9262) : 1069-1075
 
7) Patel, K. et al. : Evaluation of a panel of non-invasive serum markers to differentiate mild from moderateto-advanced liver fibrosis in chronic C patients. J Hepatol 2004 ; 41 (6) : 935-942
 
8) Adams, L. A. et al. : Hepascore : an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005 ; 51 (10) : 1867-1873
 
9) Cales, P. et al. : A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005 ; 42 (6) : 1373-1381
 
10) Hui, A. Y. et al. : Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005 ; 100 (3) : 616-623
 
11) Zeng, M. D. et al. : Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005 ; 42 (6) : 1437-1445
 
12) Angulo, P. et al. : The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007 ; 45 (4) : 846-854
 
13) Harrison, S. A. et al. : Development and validation of a simple NAFLD clinicalscoring system for identifying patients without advanced disease. Gut 2008 ; 57 (10) : 1441-1447
 
P.17 掲載の参考文献
1) Ito, K. et al. : LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 2012 ; 56 (4) : 1448-1456
 
2) Afdhal, N. et al. : Thrombocytopenia associated with chronic liver disease. J Hepatol 2008 ; 48 (6) : 1000-1007
 
3) Wang, C. S. et al. : Strong association of hepatitis C virus (HCV) infection and thrombocytopenia : implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 2004 ; 39 (6) : 790-796
 
4) Kuno, A. et al. : Evanescent-field fluorescence-assisted lectin microarray : a new strategy for glycan profiling. Nat Methods 2005 ; 2 (11) : 851-856
 
5) Kuno, A. et al. : Multilectin assay for detecting fibrosis-specific glyco-alteration by means of lectin microarray. Clin Chem 2011 ; 57 (1) : 48-56
 
6) Kuno, A. et al. : A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013 ; 3 : 1065
PubMed
7) Ito, K. et al. : Serum WFA+ -M2BP levels predict liver fibrosis, development of hepatocellular carcinoma, and overall survival : a meta-analysis. J Gastroenterol Hepatol 2017 [Epub ahead of print]
 
P.24 掲載の参考文献
1) Kuno, A. et al. : A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013 ; 3 : 1065
PubMed
2) Sato, Y. et al. : Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993 ; 328 (25) : 1802-1806
 
3) Yamasaki, K. et al. : Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014 ; 60 (5) : 1563-1570
 
4) Sasaki, R. et al. : Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One 2015 ; 10 (6) : e0129053
PubMed
5) Fujiyoshi, M. et al. : Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 2015 ; 50 (11) : 1134-1144
 
6) 是永匡紹ほか : 糖鎖マーカーを利用したNASH診断の試み. 肝胆膵 2014 ; 69 (3) : 365-472
 
7) Abe, M. et al. : Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015 ; 50 (7) : 776-784
 
8) Toyoda, H. et al. : Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int 2016 ; 36 (2) : 293-301
 
P.31 掲載の参考文献
1) Rosenberg, W. M. et al. : Serum markers detect the presence of liver fibrosis : a cohort study. Gastroenterology 2004 ; 127 (6) : 1704-1713
 
2) ADVIA Centaur Enhanced Liver Fibrosis (ELF) Test Specifications, SIEMENS (http://www.diagnosticum.hu/upload/product/advia_centaur_elf_teszt.pdf)
 
3) Lichtinghagen, R. et al. : The Enhanced Liver Fibrosis (ELF) score : normal values, influence factors and proposed cut-off values. J Hepatol 2013 ; 59 (2) : 236-242
 
4) Fagan, K. J. et al. : ELF score > 9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. Liver Int 2015 ; 35 (6) : 1673-1681
 
5) Wahl, K. et al. : Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. PLoS ONE 2012 ; 7 (12) : e51906
PubMed
6) Parkes, J. et al. : Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011 ; 18 (1) : 23-31
 
7) Mayo, M. J. et al. : Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008 ; 48 (5) : 1549-1557
 
8) Nobili, V. et al. : Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009 ; 136 (1) : 160-167
 
9) Parkes, J. et al. : Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010 ; 59 (9) : 1245-1251
 
10) Irvine, K. M. et al. : The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int 2016 ; 36 : 370-377.
PubMed
11) Crespo, G. et al. : ARFI, FibroScanR, ELF, and their combinations in the assessment of liver fibrosis : a prospective study. J Hepatol 2012 ; 57 (2) : 281-287
 
P.36 掲載の参考文献
1) Kawaguchi, T. et al. : Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012 ; 7 (6) : e38322
PubMed
2) Xu, R. et al. : Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease : a HuGE review and meta-analysis. Sci Rep 2015 ; 5 : 9284
PubMed
3) Tamaki, N. et al. : Genetic polymorphisms of IL28B and PNPLA3 are predictive for HCV related rapid fibrosis progression and identify patients who require urgent antiviral treatment with new regimens. PLoS One 2015 ; 10 (9) : e0137351
PubMed
4) Singal, A. G. et al. : The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma : a meta-analysis. Am J Gastroenterol 2014 ; 109 (3) : 325-334
 
5) Asahina, Y. et al. : Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol 2014 ; 49 (7) : 1152-1162
 
6) Sato, M. et al. : Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis : a meta-analysis. PLoS One 2014 ; 9 (3) : e91822
PubMed
7) Matsuura, K. et al. : Genome-wide association study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection. Gastroenterology 2017 ; 152 (6) : 1383-1394
 
P.44 掲載の参考文献
1) Yoshioka, K. et al. : Can non-invasive assessment of liver fibrosis replace liver biopsy? Hepatol Res 2012 ; 42 (3) : 233-240
 
2) Friedrich-Rust, M. et al. : Performance of transient elastography for the staging of liver fibrosis : a meta-analysis. Gastroenterology 2008 ; 134 (4) : 960-974
 
3) Nitta, Y. et al. : Liver stiffness, measured by transient elastography correlates with fibrosis area in liver biopsy in patients with chronic hepatitis C. Hepatol Res 2009 ; 39 (7) : 675-684
 
4) Ichino, N. et al. : A new index for non-invasive assessment of liver fibrosis. World J Gastroenterol 2010 ; 16 (38) : 4809-4816
 
5) Wong, G. L. et al. : Non-invasive assessment of liver fibrosis with transient elastography (FibroScan(R)) : applying the cut-offs of M probe to XL probe. Ann hepatol 2013 ; 12 (4) : 570-580
 
6) Masuzaki, R. et al. : Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009 ; 49 (6) : 1954-1961
 
7) Jung, K. S. et al. : Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011 ; 53 (3) : 885-894
 
8) Arima, Y. et al. : Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. Hepatol Res 2010 ; 40 (4) : 383-392
 
9) Cassinotto, C. et al. : Liver stiffness in nonalcoholic fatty liver disease : a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology 2016 ; 63 (6) : 1817-1827
PubMed
10) Sasso, M. et al. : Controlled attenuation parameter (CAP) : a novel VCTE(TM) guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis : preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010 ; 36 (11) : 1825-1835
 
P.50 掲載の参考文献
1) Yada, N. et al. : A newly developed shear wave elastography modality : with a unique reliability index. Oncology 2015 ; 89 (Suppl 2) : 53-59
 
2) Shiina, T. : JSUM ultrasound elastography practice guidelines : basics and terminology. J Med Ultrason 2013 ; 40 (4) : 309-323
 
3) Barr, R. G. et al. : WFUMB guidelines and recommendations for clinical use of ultrasound elastography : Part 2 : breast. Ultrasound Med Biol 2015 ; 41 (5) : 1148-1160
 
4) Fujimoto, K. et al. : Non-invasive evaluation of hepatic fibrosis in patients with chronic hepatitis C using elastography. MEDIX 2007 ; Suppl : 24-27
 
5) 藤本研治ほか : Real-time Tissue Elastographyを用いた肝線維化の非侵襲的評価法～Liver fibrosis index (LF Index) によるstage判定. 肝臓 2010 ; 51 (9) : 539-541
 
6) Yada, N. et al. : Assessment of liver fibrosis with real-time tissue elastography in chronic viral hepatitis. Oncology 2013 ; 84 (Suppl 1) : 13-20
 
7) Yada, N. et al. : Prospective risk analysis of hepatocellular carcinoma in patients with chronic hepatitis C by ultrasound strain elastography. Dig Dis 2016 ; 34 (6) : 650-653
 
8) Shiina, T. et al. : Mechanical model analysis for quantitative evaluation of liver fibrosis based on ultrasound tissue elasticity imaging. Jpn J Appl Phys 2012 ; 51 (7) : 07GF11 01-08
 
9) Yada, N. et al. : Noninvasive diagnosis of liver fibrosis : utility of data mining of both ultrasound elastography and serological findings to construct a decision tree. Oncology 2014 ; 87 (Suppl 1) : 63-72
 
10) Yada, N. et al. : Influence of liver inflammation on liver stiffness measurement in patients with autoimmune hepatitis evaluation by combinational elastography. Oncology 2017 ; 92 (Suppl 1) : 10-15
 
11) Yada, N. et al. : Ultrasound elastography correlates treatment response by antiviral therapy in patients with chronic hepatitis C. Oncology 2014 ; 87 (Suppl 1) : 118-123
 
12) Sporea, I. et al. : Acoustic radiation force impulse elastography for fibrosis evaluation in patients with chronic hepatitis C : an international multicenter study. Eur J Radiol 2012 ; 81 (12) : 4112-4118
 
P.55 掲載の参考文献
1) Fahey, B. J. et al. : Acoustic radiation force impulse imaging of the abdomen : demonstration of feasibility and utility. Ultrasound Med Biol 2005 ; 31 (9) : 1185-1198
 
2) Friedrich-Rust, M. et al. : Liver fibrosis in viral hepatitis : noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009 ; 252 (2) : 595-604
 
3) Karlas, T. F. et al. : Acoustic radiation force impulse (ARFI) elastography in acute liver failure : necrosis mimics cirrhosis. Z Gastroenterol 2011 ; 49 (4) : 443-448
 
4) Ebinuma, H. et al. : Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse : comparison with Fibroscan ((R)). J Gastroenterol 2011 : 46 (10) : 1238-1248
 
5) Bota, S. et al. : Factors that influence the correlation of acoustic radiation force impulse (ARFI), elastography with liver fibrosis. Med Ultrason 2011 ; 13 (2) : 135-140
 
6) Sporea, I. et al. : Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C : an international multicenter study. Eur J Radiol. 2012 ; 81 (12) : 4112-4118
 
7) European Association for Study of Liver et al. EASL-ALEH Clinical Practice Guidelines : non-invasive tests for evaluation of liver disease severity and prognosis.J Hepatol 2015 ; 63 (1) : 237-264
 
8) Kim, S. U. et al. : Liver stiffness measurement using FibroScan is influenced by serum total bilirubin in acute hepatitis. Liver Int 2009 ; 29 (6) : 810-815
 
9) Cassinotto. C. et al. : Non-invasive assessment of liver fibrosis with impulse elastography : comparison of Supersonic Shear Imaging with ARFI and FibroScan R. J Hepatol. 2014 ; 61 (3) : 550-557
 
10) Wang, H. M. et al. : Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. Liver Int 2013 ; 33 (5) : 756-761
 
11) Aoki, T. et al. : Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases. J Gastroenterol 2017 ; 52 (1) : 104-112
 
12) Takuma, Y. et al. : Portal hypertension in patients with liver cirrhosis : diagnostic accuracy of spleen stiffness. Radiology 2016 ; 279 (2) : 609-619
 
P.61 掲載の参考文献
1) Muthupillai, R. et al. : Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science 1995 ; 269 (5232) : 1854-1857
 
2) Huwart, L. et al. : Liver fibrosis : non-invasive assessment with MR elastography. NMR Biomed 2006 ; 19 (2) : 173-179
 
3) Wu, T. et al. : MR imaging of shear waves generated by focused ultrasound. Magn Reson Med 2000 ; 43 (1) : 111-115
 
4) Manduca, A. et al. : Magnetic resonance elastography : non-invasive mapping of tissue elasticity. Med Image Anal 2001 ; 5 (4) : 237-254
 
5) Morisaka, H. et al. : Comparison of diagnostic accuracies of two-and three-dimensional MR elastography of the liver. J Magn Reson Imaging 2017 ; 45 (4) : 1163-1170
 
6) 本杉宇太郎 : I-4. MRエラストグラフィ. 荒木力 (編) 腹部のMRI, 第3版, メディカル・サイエンス・インターナショナル, 2014, p.130
 
7) Shinagawa, Y. et al. : Optimization of scanning parameters for MR elastography at 3.0 T clinical unit : volunteer study. Jpn J Radiol 2014 ; 32 (7) : 441-446
 
8) Motosugi, U. et al. : Effects of gadoxetic acid on liver elasticity measurement by using magnetic resonance elastography. Magn Reson Imaging 2012 ; 30 (1) 128-132
 
9) Singh, S. et al. : Diagnostic performance of magnetic resonance elastography in staging liver fibrosis : a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 2015 ; 13 (3) 440-451, e6
 
10) Motosugi, U. et al. : Bayesian prediction for liver fibrosis staging : combined use of elastography and serum fibrosis markers. Hepatology 2013 ; 58 (1) : 450-451
 
11) Ichikawa, S. et al. : Noninvasive hepatic fibrosis staging using mr elastography : the usefulness of the bayesian prediction method. J Magn Reson Imaging 2016 ; [epub ahead of print]
 
P.66 掲載の参考文献
1) Ichikawa, T. et al. : Detection and characterization of focal liver lesions : a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrastenhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010 ; 45 (3) : 133-141
 
2) Kogita, S. et al. : Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma : correlation with histological grading and portal blood flow. Eur Radiol 2010 ; 20 (10) : 2405-2413
 
3) Sano, K. et al. : Imaging study of early hepatocellular carcinoma : usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011 ; 261 (3) : 834-844
 
4) Ogura, S. et al. : Magnetic resonance laparoscopy : a new non-invasive technique for the assessment of chronic viral liver disease. Hepatol Res 2013 ; 43 (8) : 836-845
 

第3章 臨床への展開

P.73 掲載の参考文献
1) Sebastiani, G. et al. : SAFE biopsy : a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009 ; 49 (6) : 1821-1827
 
2) Adams, L. A. et al. : Developing a new algorithm to diagnose advanced liver fibrosis : a lift or a nudge in the right direction? J Hepatol 2017 ; 66 (6) : 1111-1113
PubMed
3) Castera, L. et al. : Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010 ; 52 (2) : 191-198
 
4) Wong, G. L. et al. : Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2014 ; 39 (2) : 197-208
 
5) Petta, S. et al. : The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2015 ; 35 (5) : 1566-1573
 
P.79 掲載の参考文献
1) Yoshida, H. et al. : Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999 ; 131 (3) : 174-181
 
2) Ono, E. et al. : Platelet count reflects stage of chronic hepatitis C. Hepatol Res 1999 ; 15 (3) : 192-200
 
3) Ioannou, G. N. et al. : Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007 ; 5 (8) : 938-945
 
4) Yamasaki, K. et al. : Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014 ; 60 (5) : 1563-1570
 
5) Sasaki, R. et al. : Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One 2015 ; 10 (6) : e0129053
PubMed
6) Wai, C. T. et al. : A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 ; 38 (2) : 518-526
 
7) Sinn, D. H. et al. : Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int 2008 ; 28 (10) : 1363-1369
 
8) Hann, H. W. et al. : Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2015 ; 30 (1) : 131-138
 
9) Sterling, R. K. et al. : Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006 ; 43 (6) : 1317-1325
 
10) Ito, T. et al. : Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. J Viral Hepat 2015 ; 22 (10) : 777-783
 
11) Suh, B. et al. : Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB-4 liver fibrosis index. Cancer 2015 ; 121 (21) : 3818-3825
 
12) Sandrin, L. et al. : Transient elastography : a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003 ; 29 (12) : 1705-1713
 
13) Castera, L. et al. : Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005 ; 128 (2) : 343-350
 
14) Masuzaki, R. et al. : Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009 ; 49 (6) : 1954-1961
 
15) Ebinuma, H. et al. : Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse : comparison with Fibroscan ((R)). J Gastroenterol 2011 ; 46 (10) : 1238-1248
 
16) Aoki, T. et al. : Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases. J Gastroenterol 2017 ; 52 (1) : 104-112
 
P.88 掲載の参考文献
1) Castera, L. et al. : Non invasive evaluation of portal hypertension using transient Elastography. J Hepatol 2012 ; 56 (3) : 696-703
 
2) Berzigotti, A. et al. : Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013 ; 144 (1) : 102-111. e1
 
3) Shibata, S. et al. : Liver stiffness-spleen size-to-platelet ratio risk score detects esophageal varices in chronic liver disease. Springerplus 2016 ; 5 (1) : 998
PubMed
4) Colecchia, A. et al. : Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012 ; 143 (3) : 646-654
 
5) Takuma, Y. et al. : Measurement of spleen stiffness by acoustic radiation force impulse imaging identifies cirrhotic patients with esophageal varices. Gastroenterology 2013 ; 144 (1) : 92-101. e2
 
6) Hirooka, M. et al. : Splenic elasticity measured with real-time tissue elastography is a marker of portal hypertension. Radiology 2011 ; 261 (3) : 960-968
 
7) de Franchis, R. et al. : Expanding consensus in portal hypertension : Report of the Baveno VI Consensus Workshop : Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 ; 63 (3) : 743-752
 
8) Maurice, J. B. et al. : Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. J Hepatol 2016 ; 65 (5) : 899-905
PubMed
9) Augustin, S. et al. : Validating the Baveno VI recommendations for screening varices. J Hepatol 2017 ; 66 (2) : 459-460
 
10) Marot, A. et al. : Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. Liver Int 2017 ; 37 (5) : 707-716
 
P.95 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会 (編) : B型肝炎治療ガイドライン (第3版), 2017年8月 (https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b)
 
2) Ishii, A. et al. : Clinical implications of serum Wisteria floribunda Agglutinin-Positive Mac-2-binding protein in treatment-naive chronic hepatitis B. Hepatol Res 2017 ; 47 (2) : 204-215
 
P.101 掲載の参考文献
1) Lee, K. et al. : Prediction of the risk of hepatocellular carcinoma in chronic hepatitis C patients after sustained virological response by aspartate aminotransferase to platelet ratio index. Gut Liver 2016 ; 10 (5) : 796-802
 
2) Wu, C. K. et al. : Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. J Antimicrob Chemother 2016 ; 71 (7) : 1943-1947
 
3) Ng, K. J. et al. : Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. Clin Interv Aging 2016 ; 11 : 1035-1041
 
4) Kobayashi, M. et al. : Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 2017 ; 89 (3) : 476-483
PubMed
5) Toyoda, H. et al. : Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV. Antivir Ther 2016 ; 22 (3) : 185-193
 
6) Wang, J. H. et al. : Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. Liver Int 2016 ; 36 (12) : 1793-1799
 
7) Lee, H. W. et al. : Predicting liver-related events using transient elastography in chronic hepatitis C patients with sustained virological response. Gut Liver 2016 ; 10 (4) : 653-655
 
8) Casado, J. L. et al. : Fibrosis regression explains differences in outcome in HIV-/HCV-coinfected patients with cirrhosis after sustained virological response. Dig Dis Sci 2015 ; 60 (11) : 3473-3481
 
9) Imai, Y. et al. : The close linkage between the elasticity modulus measured by real-time mapping shear wave elastography and the presence of hepatocellular carcinoma in patients with a sustained virological response to interferon for chronic hepatitis C. J Med Ultrason 2015 ; 42 (3) : 341-347
 
10) Mototsugu, U. et al. : Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma : a preliminary case-control study. Eur Radiol 2013 ; 23 (1) : 156-162
 
11) Asahina, Y. et al. : α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013 ; 58 (4) : 1253-1262
 
12) Oze, T. et al. : Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 2014 ; 12 (7) : 1186-1195
 
13) Tachi, Y. et al. : α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. J Gastroenterol Hepatol 2016 ; 31 (5) : 1001-1008
 
14) Wu, C. K. et al. : Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. J Antimicrob Chemother 2016 ; 71 (7) : 1943-1947
 
15) Yamasaki, K. et al. : Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014 ; 60 (5) : 1563-1570
 
16) Sato, S. et al. : Prediction of hepatocellular carcinoma development after hepatitis C virus eradication using serum Wisteria floribunda agglutinin-positive Mac-2-binding protein. Int J Mol Sci. 2016 ; 17 (12) : E2143
 
17) Nagata, H. et al. : Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 2016 ; 10 (6) : 956-964
 
18) Sasaki, R. et al. : Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One 2015 ; 10 (6) : e0129053
PubMed
19) Nagata, H. et al. : Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2017 (in press)
 
20) Asahina, Y. et al. : Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol 2014 ; 49 (7) : 1152-1162
 
21) Chang, K. C. et al. : A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Clin Gastroenterol Hepatol 2015 ; 13 (5) : 1017-1024
 
22) Matsuura, K. et al. : Genome-Wide Association Study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection. Gastroenterology 2017 ; 152 (6) : 1383-1394
 
P.108 掲載の参考文献
1) 大平弘正 : 本邦における自己免疫性肝炎の現状と課題. 肝臓 2015 ; 56 (5) : 167-178
 
2) Takahashi, A. et al. : Autoimmune hepatitis in Japan : trends in a nationwide survey. J Gastroenterol 2017 ; 52 (5) : 631-640
 
3) Ohira, H. et al. : Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan. J Gastroenterol 2013 ; 48 (1) : 109-114
 
4) 大平弘正 : 原発性胆汁性肝硬変. 小俣政男ほか (監修) 専門医のための消化器病学, 第2版, 医学書院 2013, 413-418
 
5) Nishikawa, H. et al. : Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res 2016 ; 46 (7) : 613-621
 
6) Umemura, T. et al. : Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol 2015 ; 110 (6) : 857-864
 
7) Nishikawa, H. et al. : Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-γ-inducible protein-10 in primary biliary cirrhosis. Hepatol Res 2016 ; 46 (6) : 575-583
 
8) Xu, Q. et al. : Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2017 ; 32 (3) : 639-644
 
9) E. Anastasiou, O. et al. : Performance and utility of transient elastography and non-invasive markers of liver fiibrosis in patients with autoimmune hepatitis : a single centre experience. Hepat Mon 2016 ; 16 (11) : e40737
PubMed
10) Corpechot, C. et al. : Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012 ; 56 (1) : 198-208
 
11) Hartl, J. et al. : Transient elastography in autoimmune hepatitis : timing determines the impact of inflammation and fibrosis. J Hepatol 2016 ; 65 (4) : 769-775
 
12) Corpechot, C. et al. : Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006 ; 43 (5) : 1118-1124
 
13) Gomez-Dominguez, E. et al. : Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther 2008 ; 27 (5) : 441-447
 
14) Zhang, D. K. et al. : Acoustic radiation force impulse elastography for non-invasive assessment of disease stage in patients with primary biliary cirrhosis : a preliminary study. Clin Radiol 2014 ; 69 (8) : 836-840
 
15) Zhang, H. C. et al. : Primary biliary cirrhosis degree assessment by acoustic radiation force impulse imaging and hepatic fibrosis indicators. World J Gastroenterol 2016 ; 22 (22) : 5276-5284
 
16) Wang, J. et al. : Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. World J Gastroenterol 2017 ; 23 (5) : 859-868
 
P.118 掲載の参考文献
1) Younossi, Z. M. et al. : Hepatology 2015 ;
 
2) Harrison, S. A. : Nonalcoholic fatty liver disease and fibrosis progression : the good, the bad, and the unknown. Clin Gastroenterol Hepatol 2015 ; 13 (4) : 655-657
 
3) Angulo, P. et al. : Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015 ; 149 (2) : 389-397
 
4) Loomba, R. et al. : The Hierarchical Model of NAFLD : Prognostic Significance of Histologic Features in NASH. Gastroenterology 2015 ; 149 (2) : 278-281
 
5) Yoneda, M. et al. : Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol 2013 ; 48 (9) : 1051-1060
 
6) Yoneda, M. et al. : Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 2011 ; 46 (11) : 1300-1306
 
7) Yoneda, M. et al. : Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007 ; 56 (9) : 1330-1331
 
8) Nobili, V. et al : Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008 ; 48 (2) : 442-448
 
9) Wong, V. W. et al. : Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010 ; 51 (2) : 454-462
 
10) Imajo, K. et al. : Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 2016 ; 150 (3) : 626-637. e7
 
P.124 掲載の参考文献
1) Wanless, I. R. et al. : Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000 ; 124 (11) : 1599-1607
 
2) Kurosaki, M. et al. : The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol 2008 ; 48 (5) 736-742
 
3) Jimenez, W. et al. : Measurement of fibrosis in needle liver biopsies : evaluation of a colorimetric method. Hepatology 1985 ; 5 (5) : 815-818
 
4) D'Ambrosio, R. et al. : A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012 ; 56 (2) : 532-543
 
5) Calvaruso, V. et al. : Computer-assisted image analysis of liver collagen : relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 2009 ; 49 (4) : 1236-1244
 
6) Hall, A. R. et al. : Sample size requirement for digital image analysis of collagen proportionate area in cirrhotic livers. Histopathology 2013 ; 62 (3) : 421-430
 
7) Tsochatzis, E. et al. : Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. J Hepatol 2014 ; 60 (5) : 948-954
 
8) Huang, Y. et al. : Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome. J Hepatol 2014 ; 61 (1) : 22-27
 
9) Yasui, Y. et al. : Elastin fiber accumulation in liver correlates with the development of hepatocellular carcinoma. PLoS One 2016 ; 11 (4) : e0154558
PubMed
10) Dolman, G. et al. : Quantification of elastin as a predictor of clinical outcomes in cirrhosis caused by chronic hepatitis C (CHC) infection. Hepatology 2013 ; 58 (S1) : 594A
 
11) Duffield, J. S. et al. : Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005 ; 115 (1) : 56-65
 
12) Pellicoro, A. et al. : Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology 2012 ; 55 (6) : 1965-1975
 
13) Ehling, J. et al. : Elastin-based molecular MRI of liver fibrosis. Hepatology 2013 ; 58 (4) : 1517-1518
 

書評

最近チェックした商品履歴

Loading...